29-Nov-2024
No headlines found.
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 14-Nov 4:10 PM ET)
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Globe Newswire (Tue, 12-Nov 4:30 PM ET)
Globe Newswire (Mon, 16-Sep 7:30 AM ET)
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire (Wed, 4-Sep 8:00 AM ET)
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Checkpoint Therapeutics trades on the NASDAQ stock market under the symbol CKPT.
As of November 29, 2024, CKPT stock price climbed to $4.39 with 750,699 million shares trading.
CKPT has a beta of 1.06, meaning it tends to be more sensitive to market movements. CKPT has a correlation of 0.02 to the broad based SPY ETF.
CKPT has a market cap of $214.37 million. This is considered a Small Cap stock.
Last quarter Checkpoint Therapeutics reported $0 in Revenue and -$.23 earnings per share. This fell short of revenue expectation by $-10,000 and missed earnings estimates by -$.08.
In the last 3 years, CKPT traded as high as $32.71 and as low as $1.30.
The top ETF exchange traded funds that CKPT belongs to (by Net Assets): VTI, VXF, IWC.
CKPT has outperformed the market in the last year with a price return of +71.8% while the SPY ETF gained +34.1%. CKPT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +87.6% and +28.0%, respectively, while the SPY returned +8.2% and +2.9%, respectively.
CKPT support price is $4.04 and resistance is $4.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CKPT shares will trade within this expected range on the day.